---
layout: post
title: "Manufacture of Batches in Support of Original New Animal Drug Applications, Abbreviated New Animal Drug Applications, and Conditional New Animal Drug Applications; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:08:42 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-05686
original_published: 2024-03-18 00:00:00 +0000
significance: 8.00
---

# Manufacture of Batches in Support of Original New Animal Drug Applications, Abbreviated New Animal Drug Applications, and Conditional New Animal Drug Applications; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 18, 2024 00:00 UTC
**Document Number:** 2024-05686

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry (GFI) #285 entitled "Manufacture of Batches in Support of Original NADAs, ANADAs, and CNADAs." This draft guidance is intended to provide recommendations for the primary batches of drug product manufactured to support the approval or conditional approval of new animal drug products. This guidance is applicable to all original new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs), and their associated investigational new animal drug files (INADs) and generic investigational new animal drug files, respectively, as well as applications for conditional approval of new animal drugs (CNADAs).

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/03/18/2024-05686/manufacture-of-batches-in-support-of-original-new-animal-drug-applications-abbreviated-new-animal)
- API: https://www.federalregister.gov/api/v1/documents/2024-05686

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
